| Today's Big NewsMay 11, 2023 |
|
Choosing the best eCOA platform that considers the needs of patients, site staff and data requirements are all critical factors. But it takes more to reach success. Download your eCOA Technology Guide.
|
|
| By Nick Paul Taylor Innovent Biologics has strengthened its pitch for the Chinese obesity market with fresh phase 2 data. The update shows giving mazdutide, a molecule from Eli Lilly’s deep bench of obesity assets, at a higher dose dialed up the placebo-adjusted weight loss to 15.4% after 24 weeks. |
|
|
|
By James Waldron Takeda may have caught attention recently for ending work on its early-stage gene therapy R&D, but a close reading of the Japanese pharma’s latest earnings report reveals it has also culled a couple of gastrointestinal assets. |
By Nick Paul Taylor BioNTech has swiftly rejected an oral mRNA delivery technology. Barely one year after signing up to work with Matinas BioPharma, BioNTech found an initial mouse study failed to show preclinical activity—leading it to join Gilead on the list of companies to dump the biotech in recent months. |
Sponsored by ValGenesis Inc. Cell and gene therapies hold great promise but can also carry serious risks. Applying a risk-based approach during development and manufacturing increases patient safety and product quality. Read more. |
By Max Bayer Fusion Pharmaceuticals and Cyteir Therapeutics have each taken a magnifying glass to their pipeline and reshuffled priorities, shelving or shopping their backup assets. |
Sponsored by Precision for Medicine Discover Sofia Baig's vision for clinical research, data-driven insights & patient centricity at Precision for Medicine! |
By Gabrielle Masson Angelini Pharma just inked an exclusive licensing deal worth up to $505.5 million in biobucks to use JCR Pharmaceuticals’ tech in hopes of developing new epilepsy treatments. |
By Helen Floersh Scientists have released the first draft of the human pangenome reference, a new blueprint of human DNA built on data from a much more diverse cohort than the original. |
By Joseph Keenan ImmunityBio was hit with a complete response letter by the FDA for its bladder cancer prospect, sending the California-based company’s stock into a steep slide. |
By Andrea Park After watching Philips’ valuation plummet more than 60% since the onset of the June 2021 recall of millions of its respiratory devices, shareholders aren’t letting the losses slide. |
By Zoey Becker Even after top diabetes players Eli Lilly, Novo Nordisk and Sanofi slashed their insulin prices earlier this year, the companies still aren't off the hook. The CEOs of the companies—along with three PBM execs—faced intense questioning at a Bernie Sanders-led Senate committee hearing on insulin affordability. |
By Dave Muoio New survey data from the American Medical Association suggest medical liability claims are more often filed against physicians who are older, men and surgical specialists. |
By Ben Adams The Federal Trade Commission is taking a deeper look into IQVIA’s attempt to snap up Propel Media, which owns pharma digital ad specialist DeepIntent, as the regulator questions whether the deal will create an unfair playing field in the digital market for pharma ads. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we're continuing our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ Our speaking faculty features leaders from big pharma, small-mid size pharma, biotechs, and more. Save $500 when you. Register Today!
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
